Cardiovascular abnormalities in special conditions of advanced cirrhosis. The circulatory adaptative changes to specific therapeutic procedures for the management of refractory ascites

Gastroenterologia y Hepatologia

Volumn 29, Issue 4, 2006, Pages 263-272

  Pozzi, M ^a   Ratti, L ^a   Redaelli, E ^a   Guidi, C ^a   Mancia, G ^a,b  

^a SAN GERARDO HOSPITAL   (Italy)

^b Centro Interuniversitario di Fisiologia Clinica e Ipertensione   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; FUROSEMIDE; LOOP DIURETIC AGENT; SPIRONOLACTONE;

ARTERIAL PRESSURE; ASCITES; BACTERIAL PERITONITIS; CARDIOMYOPATHY; CARDIOVASCULAR FUNCTION; CIRRHOTIC CARDIOMYOPATHY SYNDROME; DISEASE COURSE; ESOPHAGUS VARICES; HEART OUTPUT; HEART RATE; HEPATORENAL SYNDROME; HUMAN; HYPERVOLEMIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PARACENTESIS; PERITONEUM VEIN SHUNT; PORTOSYSTEMIC ANASTOMOSIS; REVIEW; VASCULAR RESISTANCE;

EID: 33646240141     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13086820     Document Type: Article

References (61)

1. Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology. 1996;24:451-9.
2. Ginès P, Cárdenas A, Arroyo V, Rodés J. Management of cirrhosis and ascites. N Engl J Med. 2004;350:1646-54.
3. Llach J, Ginès P, Arroyo V, Rimola A, Tito L, Badalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology. 1988;94:482-7.
4. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet. 1991;337:776-8.
5. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8:1151-7.
6. Laffi G, Daskalopoulos G, Kronborg I, Hsueh W, Gentilini P, Zipser RD. Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. An explanation for the renal-sparing effect of sulindac. Gastroenterology. 1986;90:182-7.
7. Fernández-Seara J, Prieto J, Quiroga J, Zozaya JM, Cobos MA, Rodríguez-Eire JL, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology. 1989;97:1304-12.
8. Maroto A, Ginès P, Arroyo V, Ginès A, Salo J, Claria J, et al. Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction. Hepatology. 1993;17:788-93.
9. Tristani FE, Cohn JN. Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume expansion. J Clin Invest. 1967;46:1894-906.
10. Lebrec D. Review article: future indications for terlipressin therapy. Aliment Pharmacol Ther. 2004;20 Suppl 3:65-7.
11. Rimola A, Salmerón JM, Clemente G, Rodrigo L, Obrador A, Miranda ML, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology. 1995;21:674-9.
12. Navasa M, Rimola A, Rodés J. Bacterial infections in liver disease. Semin Liver Dis. 1997;17:323-33.
13. Llovet JM, Planas R, Morillas R, Quer JC, Cabré E, Boix J, et al. Short-term prognosis of cirrhotics with spontaneous bacterial peritonitis: multivariate study. Am J Gastroenterol. 1993;88:388-92.
14. Ruiz-del-Árbol L, Urman J, Fernández J, González M, Navasa M, Monescillo A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 2003;38:1210-8.
15. Fernández J, Navasa M, García-Pagán JC, Abraldes J, Jiménez W, Bosch J, et al. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol. 2004;41:384-90.
16. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl. 2000;64 Suppl 1:44-52.
17. Donovan CL, Marcovitz PA, Punch JD, Bach DS, Brown KA, Lucey MR, et al. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with end-stage liver disease prior to orthotopic liver transplantation. Transplantation. 1996;61:1180-8.
18. Nasraway SA, Klein RD, Spanier TB, Rohrer RJ, Freeman RB, Rand WM, et al. Hemodynamic correlates of outcome in patients undergoing orthotopic liver transplantation. Evidence for early postoperative myocardial depression. Chest. 1995;107:218-24.
19. Spanier TB, Klein RD, Nasraway SA, Rand WM, Rohrer RJ, Freeman RB, et al. Multiple organ failure after liver transplantation. Crit Care Med. 1995;23:466-73.
20. Sampathkumar P, Lerman A, Kim BY, Narr BJ, Poterucha JJ, Torsher LC, et al. Post-liver transplantation myocardial dysfunction. Liver Transpl Surg. 1998;4:399-403.
21. Navasa M, Feu F, García-Pagán JC, Jiménez W, Llach J, Rimola A, et al. Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology. 1993;17:355-60.
22. Henderson JM. Abnormal splanchnic and systemic hemodynamics of end-stage liver disease: what happens after liver transplantation? Hepatology. 1993;17:514-6.
23. Acosta F, Sansano T, Reche M, Roques V, Beltrán R, Rodríguez MA, et al. Is there a cirrhotic myocardiopathy in patients proposed for liver transplantation? Transplant Proc. 1999;31:2368.
24. Acosta F, De la Morena MG, Villegas M, Sansano T, Reche M, Beltrán R, et al. Evaluation of cardiac function before and after liver transplantation. Transplant Proc. 1999;31:2369-70.
25. González MG, Hernández-Madrid A, Sanromán AL, Monge G, De Vicente E, Barcena R. Comparison of post-liver transplantation electrocardiographic alterations between cyclosporine- and tacrolimus-treated patients. Transplant Proc. 1999;31:2423-4.
26. Williams K, Lewis JF, Davis G, Geiser EA. Dobutamine stress echocardiography in patients undergoing liver transplantation evaluation. Transplantation. 2000;69:2354-6.
27. Plotkin JS, Johnson LB, Rustgi VK, Kuo PC, Liu AD. Dobutamine stress echocardiography for orthotopic liver transplant evaluation. Transplantation. 2001;71:818.
28. Burra P, Graziotto A, Senzolo M, Bassanello M, Cillo U, Zucchetta P, et al. Myocardial perfusion scintigraphy in patients with liver cirrhosis evaluated for orthotopic liver transplantation. Transplant Proc. 2001;33:1447-8.
29. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996;23:164-76.
30. Quintero E, Ginès P, Arroyo V, Rimola A, Bory F, Planas R, et al. Paracentesis versus diuretics in the treatment of cirrhotics with tense ascites. Lancet. 1985;1:611-2.
31. Ginès P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology. 1987;93:234-41.
32. Tito L, Ginès P, Arroyo V, Planas R, Panes J, Rimola A, et al. Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology. 1990;98:146-51.
33. Guazzi M, Polese A, Magrini F, Fiorentini C, Olivari MT. Negative influences of ascites on the cardiac function of cirrhotic patients. Am J Med. 1975;59:165-70.
34. Simon DM, McCain JR, Bonkovsky HL, Wells JO, Hartle DK, Galambos JT. Effects of therapeutic paracentesis on systemic and hepatic hemodynamics and on renal and hormonal function. Hepatology. 1987;7:423-9.
35. Panos MZ, Moore K, Vlavianos P, Chambers JB, Anderson JV, Gimson AE, et al. Single, total paracentesis for tense ascites: sequential hemodynamic changes and right atrial size. Hepatology. 1990;11:662-7.
36. Pozzi M, Osculati G, Boari G, Serboli P, Colombo P, Lambrughi C, et al. Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology. 1994;106:709-19.
37. Pozzi M, Grassi G, Pecci V, Turri C, Boari G, Bolla GB, et al. Early effects of total paracentesis and albumin infusion on muscle sympathetic nerve activity in cirrhotic patients with tense ascites. J Hepatol. 1999;30:95-100.
38. Luca A, García-Pagán JC, Bosch J, Feu F, Jiménez W, Ginès A, et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology. 1995;22:753-8.
39. Sola-Vera J, Minana J, Ricart E, Planella M, González B, Torras X, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology. 2003;37:1147-53.
40. Planas R, Ginès P, Arroyo V, Llach J, Panes J, Vargas V, et al. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology. 1990;99:1736-44.
41. Ginès A, Fernández-Esparrach G, Monescillo A, Vila C, Doménech E, Abecasis R, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology. 1996;111:1002-10.
42. Ginès P, Arrovo V, Rodés J. Pharmacotherapy of ascites associated with cirrhosis. Drugs. 1992;43:316-32.
43. Salerno F. Large-volume paracentesis and volume re-expansion: can synthetic plasma expanders safely replace albumin? J Hepatol. 1992;14:143-5.
44. Ruiz-del-Árbol L, Monescillo A, Jiménez W, García-Plaza A, Arroyo V, Rodés J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology. 1997;113:579-86.
45. Ginès P, Guevara M, De Las Heras Heras D, Arroyo V. Review article: albumin for circulatory support in patients with cirrhosis. Aliment Pharmacol Ther. 2002;16 Suppl 5:24-31.
46. Vila MC, Sola R, Molina L, Andreu M, Coll S, Gana J, et al. Hemodynamic changes in patients developing effective hypovolemia after total paracentesis. J Hepatol. 1998;28:639-45.
47. Azoulay D, Castaing D, Majno P, Saliba F, Ichai P, Smail A, et al. Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. J Hepatol. 2001;35:590-7.
48. Stanley AJ, Redhead DN, Bouchier IA, Hayes PC. Acute effects of transjugular intrahepatic portosystemic stent-shunt (TIPSS) procedure on renal blood flow and cardiopulmonary hemodynamics in cirrhosis. Am J Gastroenterol. 1998;93:2463-8.
49. Huonker M, Schumacher YO, Ochs A, Sorichter S, Keul J, Rossle M. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut. 1999;44:743-8.
50. Merli M, Valeriano V, Funaro S, Attili AF, Masini A, Efrati C, et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol. 2002;97:142-8.
51. Martinet JP, Fenyves D, Legault L, Roy L, Dufresne MP, Spahr L, et al. Treatment of refractory ascites using transjugular intrahepatic portosystemic shunt (TIPS): a caution. Dig Dis Sci. 1997;42:161-6.
52. Jalan R, Redhead DN, Thomas HW, Henderson N, O'Rourke K, Dillon JF, et al. Mechanisms of changes in renal handling of sodium following transjugular intrahepatic portal systemic stent-shunt (TIPSS). Eur J Gastroenterol Hepatol. 1996;8:1111-6.
53. Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology. 2004;40:629-35.
54. Jalan R, Finlayson ND, Hayes PC. TIPSS trials: design determines outcome. Hepatology. 1997;26:1361-5.
55. Lotterer E, Wengert A, Fleig WE. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis. Hepatology. 1999;29:632-9.
56. Salerno F, Cazzaniga M, Pagnozzi G, Cirello I, Nicolini A, Meregaglia D, et al. Humoral and cardiac effects of TIPS in cirrhotic patients with different «effective» blood volume. Hepatology. 2003;38:1370-7.
57. Sanyal AJ, Genning C, Reddy KR, Wong F, Kowdley KV, Benner K, et al. The North American Study for the Treatment of Refractory Ascites. Gastroenterology. 2003;124:634-41.
58. Le Veen HH, Piccone VA Jr, Díaz CA, Langsam AA. A portosystemic shunt to selectively decompress esophageal varices. J Cardiovasc Surg (Torino). 1970;11:21-6.
59. Ginès A, Planas R, Angeli P, Guarner C, Salerno F, Ginès P, et al. Treatment of patients with cirrhosis and refractory ascites using LeVeen shunt with titanium tip: comparison with therapeutic paracentesis. Hepatology. 1995;22:124-31.
60. Henriksen JH, Malchow-Moller A, Ring-Larsen H, Jensen JL, Dietrichson O, Staehr-Johansen T, et al. Peritoneovenous shunt in treatment of ascites in patients with cirrhosis. A preliminary report with special reference to pathophysiology. Scand J Gastroenterol. 1983;18:529-35.
61. Suzuki H, Stanley AJ. Current management and novel therapeutic strategies for refractory ascites and hepatorenal syndrome. QJM. 2001;94:293-300.